{"source_url": "https://bioprocessintl.com", "url": "https://bioprocessintl.com/bioprocess-insider/facilities-capacity/celltrion-outlines-120000l-china-plant-and-corporate-rejig/", "title": "Celltrion outlines China plant and corporate rejig - Bioprocess Insider", "top_image": "https://bioprocessintl.com/wp-content/uploads/2020/01/Celltrion-google.jpg", "meta_img": "https://bioprocessintl.com/wp-content/uploads/2020/01/Celltrion-google.jpg", "images": ["https://bioprocessintl.com/wp-content/themes/bpi_2014/images/BPI_logo.jpg", "https://pbs.twimg.com/profile_images/988995524450836480/wzg6MGB8_normal.jpg", "https://bioprocessintl.com/wp-content/uploads/2020/01/Celltrion-google.jpg", "https://bioprocessintl.com/wp-content/themes/bpi_2014/images/BPI_logo-footer.png", "https://googleads.g.doubleclick.net/pagead/viewthroughconversion/1064805648/?value=0&guid=ON&script=0", "https://bioprocessintl.com/wp-content/uploads/2019/01/Insider-subscribe_mpu.png", "https://bioprocessintl.com/wp-content/uploads/2020/01/Celltrion-google-300x184.jpg", "https://bioprocessintl.com/wp-content/uploads/2019/12/BTYB_Informa_Connect_Logo_1Line_Indigo_Grad_RGB.png", "https://googleads.g.doubleclick.net/pagead/viewthroughconversion/971596663/?value=0&guid=ON&script=0"], "movies": [], "text": "Celltrion has confirmed it will build a biosimilars plant in China and may merge its healthcare and pharma units.\n\nA spokesman told Bioprocess Insider: \u201cCelltrion plans to build a plant in China in a move to directly advance into the world\u2019s second-largest biopharmaceutical market. Celltrion signed a business agreement with the city government of Wuhan and the provincial government of Hubei Province on 20 January 2020.\n\n\u201cThe company\u2019s business roadmap centers on building a plant with a production capacity of 120,000 liters in China to boost capacity amid rising demand. The plant will not only manufacture biopharmaceutical products but also include CMO business,\u201d he added.\n\nThe spokesman went on to say that \u201cCelltrion will eventually also set up its sales and manufacturing infrastructure in China and a portfolio of 16 products tailored for the Chinese market will be set up by 2030.\n\nThe comments came after Celltrion chairman Seo Jung-jin announced plans for the China plant at the JP Morgan Healthcare conference last week.\n\nAlso, according to the Yonhap News Agency, Celltrion will sell Remsima, a biosimilar version of Janssen Biotech\u2019s autoimmune disease drug Remicade (infliximab), in China.\n\nThe subcutaneous formulation of Remsima was approved by the European Commission for patients with rheumatoid arthritis in November 2019\n\nCelltrion Healthcare, the firm\u2019s distribution arm, has applied for a further extension to the marketing authorization to include inflammatory bowel disease.\n\nThis EU decision is expected in mid-2020.\n\nMerger?\n\nIn related news, Celltrion is considering merging its Celltrion Healthcare Co. and Celltrion Pharm Inc businesses.\n\nAccording to a regulatory filing published last Friday (here in Korean), the firm is conducting an internal review to assess such a merger.\n\nCelltrion Pharma is the firm\u2019s drug business, while Celltrion Healthcare handles distribution in overseas markets.\n\nAccording to the Pulse newswire, Seo shared the possibility of a merger at the JP Morgan conference.\n\nHe told delegates such a move would create synergy by integrating development, production and distribution.\n\nEnhanced ADC platform\n\nSeo also shared details of Celltrion\u2019s drug development plan, which will involve a new platform technology and drug repositioning.\n\nAccording to a company statement the tech \u2013 the Antibody Delivery Enhancing Domain (ADED) \u2013 is designed to increase the delivery efficiency of antibody-drug conjugates and their cell penetration.\n\nCelltrion said the approach \u201chas the potential to enhance cancer treatments.\u201d\n\nCelltrion partnered with ADED developer iProgen Biotech last year. At the time the firm said the plan was to develop novel ADCs against validated antibody targets, including HER2 and CD20.", "keywords": [], "meta_keywords": [""], "tags": ["Analytical", "Manufacturing", "Downstream Processing", "Business", "Upstream Processing"], "authors": ["Gareth Macdonald"], "publish_date": "Tue Jan 21 09:50:00 2020", "summary": "", "article_html": "", "meta_description": "Celltrion will build a biosimilars plant in China and may merge its healthcare and pharma units", "meta_lang": "en", "meta_favicon": "https://bioprocessintl.com/wp-content/uploads/2018/11/cropped-BPI-3-32x32.jpg", "meta_data": {"viewport": "width=device-width", "description": "Celltrion will build a biosimilars plant in China and may merge its healthcare and pharma units", "robots": "max-snippet:-1, max-image-preview:large, max-video-preview:-1", "og": {"locale": "en_US", "type": "article", "title": "Celltrion outlines China plant and corporate rejig - Bioprocess Insider", "description": "Celltrion will build a biosimilars plant in China and may merge its healthcare and pharma units", "url": "https://bioprocessintl.com/bioprocess-insider/facilities-capacity/celltrion-outlines-120000l-china-plant-and-corporate-rejig/", "site_name": "BioProcess International", "updated_time": "2020-01-22T16:45:11-05:00", "image": {"identifier": "https://bioprocessintl.com/wp-content/uploads/2020/01/Celltrion-google.jpg", "secure_url": "https://bioprocessintl.com/wp-content/uploads/2020/01/Celltrion-google.jpg", "width": 711, "height": 437}}, "article": {"section": "Facilities & Capacity", "published_time": "2020-01-21T09:50:00-05:00", "modified_time": "2020-01-22T16:45:11-05:00"}, "generator": "Powered by Slider Revolution 5.4.1 - responsive, Mobile-Friendly Slider Plugin for WordPress with comfortable drag and drop interface.", "msapplication-TileImage": "https://bioprocessintl.com/wp-content/uploads/2018/11/cropped-BPI-3-270x270.jpg"}, "canonical_link": "https://bioprocessintl.com/bioprocess-insider/facilities-capacity/celltrion-outlines-120000l-china-plant-and-corporate-rejig/"}